Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Follow-Up Questions
Who is the CEO of Phathom Pharmaceuticals Inc?
Mr. Steven Basta is the President of Phathom Pharmaceuticals Inc, joining the firm since 2025.
What is the price performance of PHAT stock?
The current price of PHAT is $13.53, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Phathom Pharmaceuticals Inc?
Phathom Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Phathom Pharmaceuticals Inc market cap?
Phathom Pharmaceuticals Inc's current market cap is $959.8M
Is Phathom Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Phathom Pharmaceuticals Inc, including 5 strong buy, 8 buy, 2 hold, 0 sell, and 5 strong sell
